|
POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). |
|
|
Consulting or Advisory Role - Novartis; Regeneron |
Research Funding - Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Varian Medical Systems |
|
|
|
Consulting or Advisory Role - Aldeyra Therapeutics; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Deciphera; ERYTECH Pharma; Five Prime Therapeutics; Inventiva Pharma; Inventiva Pharma; ipsen; Kyowa Hakko Kirin; Merck; Paradox Therapeutics |
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Polaris (Inst); Polaris (Inst); Roche/Genentech (Inst); Tesaro (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; ERYTECH Pharma (Inst); Halozyme; Mylan; Rafael Pharmaceuticals; VECT-HORUS |
Speakers' Bureau - AstraZeneca; Celgene; ERYTECH Pharma; SERVIER; Shire |
Research Funding - AstraZeneca (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Halozyme (Inst) |
Travel, Accommodations, Expenses - Halozyme; Ipsen; Pfizer/EMD Serono; Shire; Vect-Horus |
|
|
Consulting or Advisory Role - AstraZeneca; Baxalta/Shire; Baxter; Celgene; Lilly; Sanofi |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Celgene |
Other Relationship - AstraZeneca; Celgene |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Consulting or Advisory Role - Baxalta; Baxter; Celgene; Incyte; Ipsen; Lilly; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire |
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER |
|
|
Research Funding - Ambry Genetics; AstraZeneca; Caris Life Sciences; Foundation Medicine; InVitae; Myriad Genetics |
Patents, Royalties, Other Intellectual Property - I share a patent with several Fox Chase investigators for a novel method to investigate hereditary CRC genes (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Caris Life Sciences; Foundation Medicine; Myriad Genetics |
Other Relationship - Caris Life Sciences; Foundation Medicine; Invitae; Myriad Genetics |
|
|
Consulting or Advisory Role - AstraZeneca; Celgene; Merck Serono; Sanofi; SERVIER; Shire |
Speakers' Bureau - Celgene |
Research Funding - Celgene |
|
|
Stock and Other Ownership Interests - Novartis; Roche |
Speakers' Bureau - Pierre Fabre |
Research Funding - Merck Serono |
Travel, Accommodations, Expenses - Celgene |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Merck Serono; Roche/Genentech; SERVIER; TERUMO |
Consulting or Advisory Role - Bayer; Biocompatibles; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Servier; Terumo |
Research Funding - Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche/Genentech |
|
|
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks |
Research Funding - Array BioPharma; AstraZeneca; Lilly |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; MSD |
|
|
Consulting or Advisory Role - Celgene; SERVIER |
Research Funding - Chugai Pharma (Inst) |
Travel, Accommodations, Expenses - SERVIER |
|
|
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I) |
Research Funding - AstraZeneca/MedImmune (Inst) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Employment - AstraZeneca; AstraZeneca (I) |
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I) |
|
|
|
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Honoraria - MSD; Rafael Pharmaceuticals |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; MSD; Teva |
Speakers' Bureau - Abbvie; AstraZeneca |
Research Funding - AstraZeneca (Inst); MSD (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; MSD |